Drugs / GB3226
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07084584 | Jun 2026 → Jun 2029 | acute myeloid leukemia | Galecto Biotech AB | Withdrawn | No outcome recorded Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GB3226 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07084584 ↗ |
| Action | Inhibit | “GB3226: Dual inhibitor of ENL-YEATS and FLT3 pathways Administration: Oral, daily dosing in 28-day cycles” NCT07084584 ↗ |
| Route | Oral | “Administration: Oral” NCT07084584 ↗ |
| Target | FLT3 | “GB3226: Dual inhibitor of ENL-YEATS and FLT3 pathways Administration: Oral, daily dosing in 28-day cycles” NCT07084584 ↗ |